NYSTATIN ORAL SUSPENSION- nystatin suspension
Nystatin Oral Suspension by
Drug Labeling and Warnings
Nystatin Oral Suspension by is a Prescription medication manufactured, distributed, or labeled by Xttrium Laboratories, Inc.. Drug facts, warnings, and ingredients follow.
Drug Details [pdf]
- SPL UNCLASSIFIED SECTION
-
DESCRIPTION
Nystatin is an antimycotic polyene antibiotic obtained from Streptomyces noursei.
Structural formula:
C 47H 75NO 17 MW 926.13
Nystatin Oral Suspension USP, for oral administration, contains 100,000 USP Nystatin Units per mL. Inactive ingredients: alcohol (≤ 1% v/v), artificial wild cherry flavor, banana flavor, D&C Yellow #10, FD&C Red #40, glycerin, USP, magnesium aluminum silicate, methylparaben, NF, potassium phosphate dibasic, USP, propylene glycol, USP, propylparaben, NF, purified water, USP and sucrose 33.5%. May also contain citric acid, USP for pH adjustment.
-
CLINICAL PHARMACOLOGY
Pharmacokinetics
Gastrointestinal absorption of nystatin is insignificant. Most orally administered nystatin is passed unchanged in the stool. In patients with renal insufficiency receiving oral therapy with conventional dosage forms, significant plasma concentrations of nystatin may occasionally occur.
Microbiology
Nystatin is both fungistatic and fungicidal in vitro against a wide variety of yeasts and yeast-like fungi. Candida albicans demonstrates no significant resistance to nystatin in vitro on repeated subculture in increasing levels of nystatin; other Candida species become quite resistant. Generally, resistance does not develop in vivo. Nystatin acts by binding to sterols in the cell membrane of susceptible Candida species with a resultant change in membrane permeability allowing leakage of intracellular components. Nystatin exhibits no appreciable activity against bacteria, protozoa, or viruses.
- INDICATIONS AND USAGE
- CONTRAINDICATIONS
-
PRECAUTIONS
General
This medication is not to be used for the treatment of systemic mycoses. Discontinue treatment if sensitization or irritation is reported during use.
Carcinogenesis, Mutagenesis, Impairment of Fertility
No long-term animal studies have been performed to evaluate carcinogenic potential. There also have been no studies to determine mutagenicity or whether this medication affects fertility in males or females.
Pregnancy
Teratogenic Effects
Animal reproduction studies have not been conducted with nystatin oral suspension. It is also not known whether nystatin oral suspension can cause fetal harm when administered to a pregnant woman or can affect reproduction capacity. Nystatin oral suspension should be given to a pregnant woman only if clearly needed.
-
ADVERSE REACTIONS
Nystatin is well tolerated even with prolonged therapy. Oral irritation and sensitization have been reported. (See PRECAUTIONS: General).
Gastrointestinal:Diarrhea (including one case of bloody diarrhea), nausea, vomiting, gastrointestinal upset/disturbances.
Dermatologic:Rash, including urticaria has been reported rarely. Stevens-Johnson syndrome has been reported very rarely.
Other:Tachycardia, bronchospasm, facial swelling, and non-specific myalgia have also been rarely reported.
To report SUSPECTED ADVERSE REACTIONS, contact Xttrium Laboratories, Inc. at 1-800-587-3721 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.
-
OVERDOSAGE
Oral doses of nystatin in excess of five million units daily have caused nausea and gastrointestinal upset. There have been no reports of serious toxic effects of superinfections (See CLINICAL PHARMACOLOGY, Pharmacokinetics).
-
DOSAGE AND ADMINISTRATION
INFANTS: 2 mL (200,000 units) four times daily (in infants and young children, use dropper to place one-half of dose in each side of mouth and avoid feeding for 5 to 10 minutes).
NOTE: Limited clinical studies in premature and low birth weight infants indicate that 1 mL four times daily is effective.
CHILDREN AND ADULTS: 4-6 mL (400,000 to 600,000 units) four times daily (one-half of dose in each side of mouth). The preparation should be retained in the mouth as long as possible before swallowing.
Continue treatment for at least 48 hours after perioral symptoms have disappeared and cultures demonstrate eradication of Candida albicans.
-
HOW SUPPLIED
Nystatin Oral Suspension USP, 100,000 USP Nystatin Units per mL, is available as a fruit flavored, light creamy yellow, ready-to-use suspension.
60 mL bottle was a calibrated dropper and
1 Pint (473 mL) bottles (0116-4026-16)
- SPL UNCLASSIFIED SECTION
-
PRINCIPAL DISPLAY PANEL - 60 mL Bottle Label
NDC: 0116-4026-16
NYSTATIN ORAL SUSPENSION, USP
(100,000 units per mL)
Each mL contains: 100,000 units Nystatin, USP with the following inactive ingredients: alcohol (≤ 1% v/v), artificial wild cherry flavor, banana flavor, D&C yellow #10, FD&C red #40, glycerin, USP, magnesium aluminum silicate, methyl paraben, NF, potassium phosphate dibasic, USP, propylene glycol, USP, propylparaben, NF, purified water, USP and sucrose 33.5%.
May also contain citric acid, USP for Ph adjustment.
Fruit Flavored
SHAKE WELL BEFORE USING
Rx Only
NET: 1 Pint (473 mL)USUAL DOSAGE: For infants: 2 mL (200,000 units) four times daily (in infants and young children, use dropper to place one-half of dose in each side of mouth and avoid feeding for 5 to 10 minutes).
USUAL DOSAGE: For Children and Adults: See package insert.
WARNINGS: Keep this and all drugs out of the reach of children.
In case of accidental overdose, seek professional assistance or contact a Poison Control Center immediately.
Store at 20° to 25°C (68° to 77°F) [see USP Controlled Room Temperature].
AVOID FREEZING
Dispense in a tight, light-resistant container as defined in the USP.
Manufactured by:
Xttrium Laboratories, Inc.
1200 E. Business Center Dr.
Mount Prospect, IL 60056
402616BTLLBL REV. 09-25
-
PRINCIPAL DISPLAY PANEL - 5 mL Unit Dose Cup Label
UNIT DOSE
Delivers 5 mL
NDC: 0116-4026-05
NYSTATIN
ORAL SUSPENSION, USP
500,000 units / 5 mL
Alcohol ≤ 1% v/v SHAKE WELLInstitutional Use Only
Rx Only
Xttrium Laboratories, Inc.
Mount Prospect, IL
SEE INSERT
-
INGREDIENTS AND APPEARANCE
NYSTATIN ORAL SUSPENSION
nystatin suspensionProduct Information Product Type HUMAN PRESCRIPTION DRUG Item Code (Source) NDC: 0116-4026 Route of Administration ORAL Active Ingredient/Active Moiety Ingredient Name Basis of Strength Strength NYSTATIN (UNII: BDF1O1C72E) (NYSTATIN - UNII:BDF1O1C72E) NYSTATIN 100000 [USP'U] in 1 mL Inactive Ingredients Ingredient Name Strength SUCROSE (UNII: C151H8M554) ALCOHOL (UNII: 3K9958V90M) ANHYDROUS CITRIC ACID (UNII: XF417D3PSL) D&C YELLOW NO. 10 (UNII: 35SW5USQ3G) FD&C RED NO. 40 (UNII: WZB9127XOA) GLYCERIN (UNII: PDC6A3C0OX) METHYLPARABEN (UNII: A2I8C7HI9T) POTASSIUM PHOSPHATE, DIBASIC (UNII: CI71S98N1Z) PROPYLENE GLYCOL (UNII: 6DC9Q167V3) PROPYLPARABEN (UNII: Z8IX2SC1OH) WATER (UNII: 059QF0KO0R) MAGNESIUM ALUMINUM SILICATE (UNII: 6M3P64V0NC) CHERRY (UNII: BUC5I9595W) BANANA (UNII: 4AJZ4765R9) Product Characteristics Color yellow (Light - Creamy) Score Shape Size Flavor CHERRY (Banana) Imprint Code Contains Packaging # Item Code Package Description Marketing Start Date Marketing End Date 1 NDC: 0116-4026-16 473 mL in 1 BOTTLE, PLASTIC; Type 0: Not a Combination Product 02/09/2026 2 NDC: 0116-4026-50 5 in 1 CASE 02/09/2026 2 10 in 1 TRAY 2 NDC: 0116-4026-05 5 mL in 1 CUP, UNIT-DOSE; Type 0: Not a Combination Product 3 NDC: 0116-4026-11 10 in 1 CASE 02/06/2026 3 10 in 1 TRAY 3 NDC: 0116-4026-05 5 mL in 1 CUP, UNIT-DOSE; Type 0: Not a Combination Product Marketing Information Marketing Category Application Number or Monograph Citation Marketing Start Date Marketing End Date ANDA ANDA062512 02/06/2026 Labeler - Xttrium Laboratories, Inc. (007470579) Registrant - Xttrium Laboratories, Inc. (007470579) Establishment Name Address ID/FEI Business Operations Xttrium Laboratories, Inc. 007470579 label(0116-4026) , manufacture(0116-4026) , pack(0116-4026)
© 2026 FDA.report
This site is not affiliated with or endorsed by the FDA.